Search

Your search keyword '"Tijssen J"' showing total 835 results
Start Over Author "Tijssen J"
835 results on '"Tijssen J"'

1. Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries

Author

Dutt C, Nunes Salles JE, Joshi S, Nair T, Chowdhury S, Mithal A, Mohan V, Kasliwal R, Sharma S, Tijssen J, and Tandon N

Subjects
mitochondrial modulator, insulin resistance, diabetes mellitus, dyslipidemia hypertension, non-high density lipoprotein-cholesterol, triglycerides, apolipoprotein b, Specialties of internal medicine, RC581-951
Abstract

Chaitanya Dutt,1 Joao Eduardo Nunes Salles,2 Shashank Joshi,3 Tiny Nair,4 Subhankar Chowdhury,5 Ambrish Mithal,6 Viswanathan Mohan,7 Ravi Kasliwal,8 Satyawan Sharma,9 Jan Tijssen,10 Nikhil Tandon11 1Research and Development, Torrent Pharmaceuticals Ltd, Ahmedabad, Gujarat, India; 2Discipline of Endocrinology, Medical Sciences of Santa Casa de São Paulo, São Paulo, Brazil; 3Department of Endocrinology, Lilavati Hospital, Mumbai, Maharashtra, India; 4Department of Cardiology, PRS Hospital, Thiruvananthapuram, Kerala, India; 5Department of Endocrinology, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India; 6Department of Endocrinology & Diabetes, Max Healthcare, New Delhi, India; 7Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India; 8Medanta- The Medicity, Gurgaon, Haryana, India; 9Department of Cardiology, Bombay Hospital and Medical Research Center, Mumbai, Maharashtra, India; 10Academic Medical Center - University of Amsterdam, Amsterdam, the Netherlands; 11Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, IndiaCorrespondence: Chaitanya Dutt, Research & Development, Torrent Pharmaceuticals Ltd., Ahmedabad, Gujarat, India, Tel +91 9825606901, Email Cdutt@torrentpharma.comAbstract: The epidemic of obesity or adiposity-based chronic diseases presents a significant challenge with the rising prevalence of morbidities and mortality due to atherosclerotic cardiovascular diseases (ASCVD), especially in low- and middle-income countries (LMIC). The underlying pathophysiology of metabolic inflexibility is a common thread linking insulin resistance to cardiometabolic-based chronic disease (CMBCD), including dysglycemia, hypertension, and dyslipidemia progressing to downstream ASCVD events. The complex CMBCD paradigm in the LMIC population within the socio-economic and cultural context highlights considerable heterogeneity of disease predisposition, clinical patterns, and socio-medical needs. This review intends to summarize the current knowledge of CMBCD. We describe recently established or emerging trends for managing risk factors, assessment tools for evaluating ASCVD risk, and various pharmacological and non-pharmacological measures particularly relevant for LMICs. A CMBCD model positions insulin resistance and β-cell dysfunction at the summit of the disease spectrum may improve outcomes at a lower cost in LMICs. Despite identifying multiple pathophysiologic disturbances constituting CMBCD, a large percentage of the patient at risk for ASCVD remains undefined. Targeting dysglycemia, dyslipidemia, and hypertension using antihypertensive, statins, anti-glycemic, and antiplatelet agents has reduced the incidence of ASCVD. Thus, primordial prevention targeting pathophysiological changes that cause abnormalities in adiposity and primary prevention by detecting and managing risk factors remains the foundation for CMBCD management. Therefore, targeting pathways that address mitochondrial dysfunction would exert a beneficial effect on metabolic inflexibility that may potentially correct insulin resistance, β cell dysfunction and, consequently, would be therapeutically effective across the entire continuum of CMBCD.Keywords: mitochondrial modulator, insulin resistance, diabetes mellitus, dyslipidemia hypertension, non-high-density lipoprotein-cholesterol, triglycerides, apolipoprotein B

Published
2022

6. OP0072 LOW-DOSE COLCHICINE IS ASSOCIATED WITH LOWER INCIDENCE OF KNEE AND HIP REPLACEMENTS: A POST-HOC ANALYSIS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Author

Heijman, M., primary, Fiolet, A., additional, Mosterd, A., additional, Tijssen, J., additional, Van den Bemt, B., additional, Schut, A., additional, Eikelboom, J., additional, Thompson, P., additional, Van den Ende, C., additional, Nidorf, S., additional, Popa, C., additional, and Cornel, J. H., additional

Published
2023
Full Text
View/download PDF

7. 2023 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces

Author

Berg, K. M., Bray, J. E., Ng, K. -C., Liley, H. G., Greif, R., Carlson, J. N., Morley, P. T., Drennan, I. R., Smyth, M., Scholefield, B. R., Weiner, G. M., Cheng, A., Djarv, T., Abelairas-Gomez, C., Acworth, J., Andersen, L. W., Atkins, D. L., Berry, D. C., Bhanji, F., Bierens, J., Couto, T. B., Borra, V., Bottiger, B. W., Bradley, R. N., Breckwoldt, J., Cassan, P., Chang, W. -T., Charlton, N. P., Chung, S. P., Considine, J., Costa-Nobre, D. T., Couper, K., Dainty, K. N., Dassanayake, V., Davis, P. G., Dawson, J. A., de Almeida, M. F., De Caen, A. R., Deakin, C. D., Dicker, B., Douma, M. J., Eastwood, K., El-Naggar, W., Fabres, J. G., Fawke, J., Fijacko, N., Finn, J. C., Flores, G. E., Foglia, E. E., Folke, F., Gilfoyle, E., Goolsby, C. A., Granfeldt, A., Guerguerian, A. -M., Guinsburg, R., Hatanaka, T., Hirsch, K. G., Holmberg, M. J., Hosono, S., Hsieh, M. -J., Hsu, C. H., Ikeyama, T., Isayama, T., Johnson, N. J., Kapadia, V. S., Kawakami, M. D., Kim, H. -S., Kleinman, M. E., Kloeck, D. A., Kudenchuk, P., Kule, A., Kurosawa, H., Lagina, A. T., Lauridsen, K. G., Lavonas, E. J., Lee, H. C., Lin, Y., Lockey, A. S., Macneil, F., Maconochie, I. K., Madar, R. J., Hansen, C. M., Masterson, S., Matsuyama, T., Mckinlay, C. J. D., Meyran, D., Monnelly, V., Nadkarni, V., Nakwa, F. L., Nation, K. J., Nehme, Z., Nemeth, M., Neumar, R. W., Nicholson, T., Nikolaou, N., Nishiyama, C., Norii, T., Nuthall, G. A., Ohshimo, S., Olasveengen, T. M., Ong, Y. -K. G., Orkin, A. M., Parr, M. J., Patocka, C., Perkins, G. D., Perlman, J. M., Rabi, Y., Raitt, J., Ramachandran, S., Ramaswamy, V. V., Raymond, T. T., Reis, A. G., Reynolds, J. C., Ristagno, G., Rodriguez-Nunez, A., Roehr, C. C., Rudiger, M., Sakamoto, T., Sandroni, Claudio, Sawyer, T. L., Schexnayder, S. M., Schmolzer, G. M., Schnaubelt, S., Semeraro, F., Singletary, E. M., Skrifvars, M. B., Smith, C. M., Soar, J., Stassen, W., Sugiura, T., Tijssen, J. A., Topjian, A. A., Trevisanuto, D., Vaillancourt, C., Wyckoff, M. H., Wyllie, J. P., Yang, C. -W., Yeung, J., Zelop, C. M., Zideman, D. A., Nolan, J. P., Barcala-Furelos, R., Beerman, S. B., Bruckner, M., Castren, M., Chong, S., Claesson, A., Dunne, C. L., Finan, E., Fukuda, T., Ganesan, S. L., Gately, C., Gois, A., Gray, S., Halamek, L. P., Hoover, A. V., Hurst, C., Josephsen, J., Kollander, L., Kamlin, C. O., Kool, M., Li, L., Mecrow, T. S., Montgomery, W., Ristau, P., Jayashree, M., Schmidt, A., Scquizzato, T. -M., Seesink, J., Sempsrott, J., Solevag, A. L., Strand, M. L., Szpilman, D., Szyld, E., Thom, O., Tobin, J. M., Trang, J., Webber, J., Webster, H. K., Wellsford, M., Sandroni C. (ORCID:0000-0002-8878-2611), Berg, K. M., Bray, J. E., Ng, K. -C., Liley, H. G., Greif, R., Carlson, J. N., Morley, P. T., Drennan, I. R., Smyth, M., Scholefield, B. R., Weiner, G. M., Cheng, A., Djarv, T., Abelairas-Gomez, C., Acworth, J., Andersen, L. W., Atkins, D. L., Berry, D. C., Bhanji, F., Bierens, J., Couto, T. B., Borra, V., Bottiger, B. W., Bradley, R. N., Breckwoldt, J., Cassan, P., Chang, W. -T., Charlton, N. P., Chung, S. P., Considine, J., Costa-Nobre, D. T., Couper, K., Dainty, K. N., Dassanayake, V., Davis, P. G., Dawson, J. A., de Almeida, M. F., De Caen, A. R., Deakin, C. D., Dicker, B., Douma, M. J., Eastwood, K., El-Naggar, W., Fabres, J. G., Fawke, J., Fijacko, N., Finn, J. C., Flores, G. E., Foglia, E. E., Folke, F., Gilfoyle, E., Goolsby, C. A., Granfeldt, A., Guerguerian, A. -M., Guinsburg, R., Hatanaka, T., Hirsch, K. G., Holmberg, M. J., Hosono, S., Hsieh, M. -J., Hsu, C. H., Ikeyama, T., Isayama, T., Johnson, N. J., Kapadia, V. S., Kawakami, M. D., Kim, H. -S., Kleinman, M. E., Kloeck, D. A., Kudenchuk, P., Kule, A., Kurosawa, H., Lagina, A. T., Lauridsen, K. G., Lavonas, E. J., Lee, H. C., Lin, Y., Lockey, A. S., Macneil, F., Maconochie, I. K., Madar, R. J., Hansen, C. M., Masterson, S., Matsuyama, T., Mckinlay, C. J. D., Meyran, D., Monnelly, V., Nadkarni, V., Nakwa, F. L., Nation, K. J., Nehme, Z., Nemeth, M., Neumar, R. W., Nicholson, T., Nikolaou, N., Nishiyama, C., Norii, T., Nuthall, G. A., Ohshimo, S., Olasveengen, T. M., Ong, Y. -K. G., Orkin, A. M., Parr, M. J., Patocka, C., Perkins, G. D., Perlman, J. M., Rabi, Y., Raitt, J., Ramachandran, S., Ramaswamy, V. V., Raymond, T. T., Reis, A. G., Reynolds, J. C., Ristagno, G., Rodriguez-Nunez, A., Roehr, C. C., Rudiger, M., Sakamoto, T., Sandroni, Claudio, Sawyer, T. L., Schexnayder, S. M., Schmolzer, G. M., Schnaubelt, S., Semeraro, F., Singletary, E. M., Skrifvars, M. B., Smith, C. M., Soar, J., Stassen, W., Sugiura, T., Tijssen, J. A., Topjian, A. A., Trevisanuto, D., Vaillancourt, C., Wyckoff, M. H., Wyllie, J. P., Yang, C. -W., Yeung, J., Zelop, C. M., Zideman, D. A., Nolan, J. P., Barcala-Furelos, R., Beerman, S. B., Bruckner, M., Castren, M., Chong, S., Claesson, A., Dunne, C. L., Finan, E., Fukuda, T., Ganesan, S. L., Gately, C., Gois, A., Gray, S., Halamek, L. P., Hoover, A. V., Hurst, C., Josephsen, J., Kollander, L., Kamlin, C. O., Kool, M., Li, L., Mecrow, T. S., Montgomery, W., Ristau, P., Jayashree, M., Schmidt, A., Scquizzato, T. -M., Seesink, J., Sempsrott, J., Solevag, A. L., Strand, M. L., Szpilman, D., Szyld, E., Thom, O., Tobin, J. M., Trang, J., Webber, J., Webster, H. K., Wellsford, M., and Sandroni C. (ORCID:0000-0002-8878-2611)

Abstract

The International Liaison Committee on Resuscitation engages in a continuous review of new, peer-reviewed, published cardiopulmonary resuscitation and first aid science. Draft Consensus on Science With Treatment Recommendations are posted online throughout the year, and this annual summary provides more concise versions of the final Consensus on Science With Treatment Recommendations from all task forces for the year. Topics addressed by systematic reviews this year include resuscitation of cardiac arrest from drowning, extracorporeal cardiopulmonary resuscitation for adults and children, calcium during cardiac arrest, double sequential defibrillation, neuroprognostication after cardiac arrest for adults and children, maintaining normal temperature after preterm birth, heart rate monitoring methods for diagnostics in neonates, detection of exhaled carbon dioxide in neonates, family presence during resuscitation of adults, and a stepwise approach to resuscitation skills training. Members from 6 International Liaison Committee on Resuscitation task forces have assessed, discussed, and debated the quality of the evidence, using Grading of Recommendations Assessment, Development, and Evaluation criteria, and their statements include consensus treatment recommendations. Insights into the deliberations of the task forces are provided in the Justification and Evidence-to-Decision Framework Highlights sections. In addition, the task forces list priority knowledge gaps for further research. Additional topics are addressed with scoping reviews and evidence updates.

Published
2023

9. Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator

Author

van Barreveld, M., Dijkgraaf, M. G. W., Hulleman, M., Boersma, L. V. A., Delnoy, P. P. H. M., Meine, M., Tuinenburg, A. E., Theuns, D. A. M. J., van der Voort, P. H., Kimman, G. P., Buskens, E., Tijssen, J. P. G., Bruinsma, N., Verstraelen, T. E., Zwinderman, A. H., van Dessel, P. H. F. M., Wilde, A. A. M., and on behalf of the DO-IT investigators

Published
2017
Full Text
View/download PDF

14. PP215 [Family Care » Other]: ASSOCIATION BETWEEN INVITATION METHOD AND RESPONSE RATE: RESULTS OF A MULTI-CENTERED NATIONAL SURVEY OF CANADIAN PICU FAMILIES

Author

Ryan, M. J., primary, Lee, L., additional, Garros, D., additional, O’Hearn, K., additional, Seabrook, J., additional, Barclay, A., additional, Choong, K., additional, Fontela, P., additional, Murthy, S., additional, Nicoll, J., additional, Sehgal, A., additional, Tijssen, J. A., additional, and Foster, J. R., additional

Published
2022
Full Text
View/download PDF

15. The effects of colchicine in patients with diabetes mellitus and chronic coronary artery disease: a post-hoc analysis of the LoDoCo2-trial

Author

Mohammadnia, N, primary, Los, J, additional, Opstal, T S J, additional, Fiolet, A T L, additional, Eikelboom, J W, additional, Mosterd, A, additional, Nidorf, S M, additional, Budgeon, C A, additional, Tijssen, J G P, additional, Thompson, P L, additional, Tack, C J, additional, Simsek, S, additional, Bax, W A, additional, Cornel, J H, additional, and El Messaoudi, S, additional

Published
2022
Full Text
View/download PDF

16. End-of-trial inflammatory biomarkers, lipid levels, creatine kinase and markers of renal and liver function in the LoDoCo2 trial

Author

Van Broekhoven, A, primary, Mohammadnia, N, additional, Silvis, M J M, additional, Los, J, additional, Fiolet, A T L, additional, Opstal, T S J, additional, Mosterd, A, additional, Eikelboom, J W, additional, Nidorf, S M, additional, Bax, W A, additional, Tijssen, J G P, additional, De Kleijn, D P V, additional, Thompson, P L, additional, El Messaoudi, S, additional, and Cornel, J H, additional

Published
2022
Full Text
View/download PDF

18. COMPARE LAAO: Rationale and design of the randomized controlled trial 'COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy'

Author

Huijboom, M., Maarse, M., Aarnink, E., Dijk, V. van, Swaans, M., Heijden, J. van der, Ijsselmuiden, S., Folkeringa, R., Blaauw, Y., Elvan, A., Stevenhagen, J., Vlachojannis, G., Voort, P. van der, Westra, S.W., Chaldoupi, M., Khan, M., Groot, J., Kley, F. van der, Mieghem, N. van, Dijk, E.J. van, Dijkgraaf, M., Tijssen, J., Boersma, L., Huijboom, M., Maarse, M., Aarnink, E., Dijk, V. van, Swaans, M., Heijden, J. van der, Ijsselmuiden, S., Folkeringa, R., Blaauw, Y., Elvan, A., Stevenhagen, J., Vlachojannis, G., Voort, P. van der, Westra, S.W., Chaldoupi, M., Khan, M., Groot, J., Kley, F. van der, Mieghem, N. van, Dijk, E.J. van, Dijkgraaf, M., Tijssen, J., and Boersma, L.

Abstract

Contains fulltext : 252137.pdf (Publisher’s version ) (Open Access), BACKGROUND: Left atrial appendage occlusion (LAAO) provides an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). In patients with a long-term or permanent contraindication for OAC randomized controlled trial (RCT) data is lacking. STUDY OBJECTIVES: To assess the efficacy and safety of LAAO in AF patients who are ineligible to use OAC. The co-primary efficacy endpoint is (1) time to first occurrence of stroke (ischemic, hemorrhagic, or undetermined) and (2) time to first occurrence of the composite of stroke, transient ischemic attack (TIA), and systemic embolism (SE). The primary safety endpoint is the 30-day rate of peri-procedural complications. STUDY DESIGN: This is a multicenter, investigator-initiated, open-label, blinded endpoint (PROBE), superiority-driven RCT. Patients with AF, a CHA₂DS₂-VASc score ≥2 for men and ≥3 for women and a long-term or permanent contraindication for OAC will be randomized in a 2:1 fashion to the device- or control arm. Patients in the device arm will undergo percutaneous LAAO and will receive post-procedural dual antiplatelet therapy (DAPT) per protocol, while those in the control arm will continue their current treatment consisting of no antithrombotic therapy or (D)APT as deemed appropriate by the primary responsible physician. In this endpoint-driven trial design, assuming a 50% lower stroke risk of LAAO compared to conservative treatment, 609 patients will be followed for a minimum of 1 and a maximum of 5 years. Cost-effectiveness and budget impact analyses will be performed to allow decision-making on reimbursement of LAAO for the target population in the Netherlands. SUMMARY: The COMPARE LAAO trial will investigate the clinical superiority in preventing thromboembolic events and cost-effectiveness of LAAO in AF patients with a high thromboembolic risk and a contraindication for OAC use. NCT TRIAL NUMBER: NCT04676880.

Published
2022

19. Do paediatric early warning systems reduce mortality and critical deterioration events among children? A systematic review and meta-analysis

Author

Chong, S-L, Goh, MSL, Ong, GY-K, Acworth, J, Sultana, R, Yao, SHW, Ng, KC, Scholefield, B, Aickin, R, Maconochie, I, Atkins, D, Couto, TB, Guerguerian, A-M, Kleinman, M, Kloeck, D, Nadkarni, V, Nuthall, G, Reis, A, Rodriguez-Nunez, A, Schexnayder, S, Tijssen, J, Van de Voorde, P, Morley, P, Chong, S-L, Goh, MSL, Ong, GY-K, Acworth, J, Sultana, R, Yao, SHW, Ng, KC, Scholefield, B, Aickin, R, Maconochie, I, Atkins, D, Couto, TB, Guerguerian, A-M, Kleinman, M, Kloeck, D, Nadkarni, V, Nuthall, G, Reis, A, Rodriguez-Nunez, A, Schexnayder, S, Tijssen, J, Van de Voorde, P, and Morley, P

Abstract

AIM: We conducted a systematic review and meta-analysis to answer the question: Does the implementation of Paediatric Early Warning Systems (PEWS) in the hospital setting reduce mortality, cardiopulmonary arrests, unplanned codes and critical deterioration events among children, as compared to usual care without PEWS? METHODS: We conducted a comprehensive search using Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature and Web of Science. We included studies published between January 2006 and April 2022 on children <18 years old performed in inpatient units and emergency departments, and compared patient populations with PEWS to those without PEWS. We excluded studies without a comparator, case control studies, systematic reviews, and studies published in non-English languages. We employed a random effects meta-analysis and synthesised the risk and rate ratios from individual studies. We used the Scottish Intercollegiate Guidelines Network (SIGN) to appraise the risk of bias. RESULTS: Among 911 articles screened, 15 were included for descriptive analysis. Fourteen of the 15 studies were pre- versus post-implementation studies and one was a multi-centre cluster randomised controlled trial (RCT). Among 10 studies (580,604 hospital admissions) analysed for mortality, we found an increased risk (pooled RR 1.18, 95% CI 1.01-1.38, p = 0.036) in the group without PEWS compared to the group with PEWS. The sensitivity analysis performed without the RCT (436,065 hospital admissions) showed a non-significant relationship (pooled RR 1.17, 95% CI 0.98-1.40, p = 0.087). Among four studies (168,544 hospital admissions) analysed for unplanned code events, there was an increased risk in the group without PEWS (pooled RR 1.73, 95%CI 1.01-2.96, p = 0.046) There were no differences in the rate of cardiopulmonary arrests or critical deterioration events between groups. Our findings were limited by potential confounder

Published
2022

20. 2022 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations: Summary from the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; And First Aid Task Forces

Author

Wyckoff, M. H., Greif, R., Morley, P. T., Ng, K. -C., Olasveengen, T. M., Singletary, E. M., Soar, J., Cheng, A., Drennan, I. R., Liley, H. G., Scholefield, B. R., Smyth, M. A., Welsford, M., Zideman, D. A., Acworth, J., Aickin, R., Andersen, L. W., Atkins, D., Berry, D. C., Bhanji, F., Bierens, J., Borra, V., Bottiger, B. W., Bradley, R. N., Bray, J. E., Breckwoldt, J., Callaway, C. W., Carlson, J. N., Cassan, P., Castren, M., Chang, W. -T., Charlton, N. P., Chung, S. P., Considine, J., Costa-Nobre, D. T., Couper, K., Couto, T. B., Dainty, K. N., Davis, P. G., De Almeida, M. F., De Caen, A. R., Deakin, C. D., Djarv, T., Donnino, M. W., Douma, M. J., Duff, J. P., Dunne, C. L., Eastwood, K., El-Naggar, W., Fabres, J. G., Fawke, J., Finn, J., Foglia, E. E., Folke, F., Gilfoyle, E., Goolsby, C. A., Granfeldt, A., Guerguerian, A. -M., Guinsburg, R., Hirsch, K. G., Holmberg, M. J., Hosono, S., Hsieh, M. -J., Hsu, C. H., Ikeyama, T., Isayama, T., Johnson, N. J., Kapadia, V. S., Kawakami, M. D., Kim, H. -S., Kleinman, M., Kloeck, D. A., Kudenchuk, P. J., Lagina, A. T., Lauridsen, K. G., Lavonas, E. J., Lee, H. C., Lin, Y. (., Lockey, A. S., Maconochie, I. K., Madar, R. J., Malta Hansen, C., Masterson, S., Matsuyama, T., Mckinlay, C. J. D., Meyran, D., Morgan, P., Morrison, L. J., Nadkarni, V., Nakwa, F. L., Nation, K. J., Nehme, Z., Nemeth, M., Neumar, R. W., Nicholson, T., Nikolaou, N., Nishiyama, C., Norii, T., Nuthall, G. A., O'Neill, B. J., Ong, Y. -K. G., Orkin, A. M., Paiva, E. F., Parr, M. J., Patocka, C., Pellegrino, J. L., Perkins, G. D., Perlman, J. M., Rabi, Y., Reis, A. G., Reynolds, J. C., Ristagno, G., Rodriguez-Nunez, A., Roehr, C. C., Rudiger, M., Sakamoto, T., Sandroni, Claudio, Sawyer, T. L., Schexnayder, S. M., Schmolzer, G. M., Schnaubelt, S., Semeraro, F., Skrifvars, M. B., Smith, C. M., Sugiura, T., Tijssen, J. A., Trevisanuto, D., Van De Voorde, P., Wang, T. -L., Weiner, G. M., Wyllie, J. P., Yang, C. -W., Yeung, J., Nolan, J. P., Berg, K. M., Burdick, M. C., Cartledge, S., Dawson, J. A., Elgohary, M. M., Ersdal, H. L., Finan, E., Flaatten, H. I., Flores, G. E., Fuerch, J., Garg, R., Gately, C., Goh, M., Halamek, L. P., Handley, A. J., Hatanaka, T., Hoover, A., Issa, M., Johnson, S., Kamlin, C. O., Ko, Y. -C., Kule, A., Leone, T. A., Mackenzie, E., Macneil, F., Montgomery, W., O'Dochartaigh, D., Ohshimo, S., Palazzo, F. S., Picard, C., Quek, B. H., Raitt, J., Ramaswamy, V. V., Scapigliati, Andrea, Shah, B. A., Stewart, C., Strand, M. L., Szyld, E., Thio, M., Topjian, A. A., Udaeta, E., Vaillancourt, C., Wetsch, W. A., Wigginton, J., Yamada, N. K., Yao, S., Zace, D., Zelop, C. M., Sandroni C. (ORCID:0000-0002-8878-2611), Scapigliati A. (ORCID:0000-0002-4044-2343), Wyckoff, M. H., Greif, R., Morley, P. T., Ng, K. -C., Olasveengen, T. M., Singletary, E. M., Soar, J., Cheng, A., Drennan, I. R., Liley, H. G., Scholefield, B. R., Smyth, M. A., Welsford, M., Zideman, D. A., Acworth, J., Aickin, R., Andersen, L. W., Atkins, D., Berry, D. C., Bhanji, F., Bierens, J., Borra, V., Bottiger, B. W., Bradley, R. N., Bray, J. E., Breckwoldt, J., Callaway, C. W., Carlson, J. N., Cassan, P., Castren, M., Chang, W. -T., Charlton, N. P., Chung, S. P., Considine, J., Costa-Nobre, D. T., Couper, K., Couto, T. B., Dainty, K. N., Davis, P. G., De Almeida, M. F., De Caen, A. R., Deakin, C. D., Djarv, T., Donnino, M. W., Douma, M. J., Duff, J. P., Dunne, C. L., Eastwood, K., El-Naggar, W., Fabres, J. G., Fawke, J., Finn, J., Foglia, E. E., Folke, F., Gilfoyle, E., Goolsby, C. A., Granfeldt, A., Guerguerian, A. -M., Guinsburg, R., Hirsch, K. G., Holmberg, M. J., Hosono, S., Hsieh, M. -J., Hsu, C. H., Ikeyama, T., Isayama, T., Johnson, N. J., Kapadia, V. S., Kawakami, M. D., Kim, H. -S., Kleinman, M., Kloeck, D. A., Kudenchuk, P. J., Lagina, A. T., Lauridsen, K. G., Lavonas, E. J., Lee, H. C., Lin, Y. (., Lockey, A. S., Maconochie, I. K., Madar, R. J., Malta Hansen, C., Masterson, S., Matsuyama, T., Mckinlay, C. J. D., Meyran, D., Morgan, P., Morrison, L. J., Nadkarni, V., Nakwa, F. L., Nation, K. J., Nehme, Z., Nemeth, M., Neumar, R. W., Nicholson, T., Nikolaou, N., Nishiyama, C., Norii, T., Nuthall, G. A., O'Neill, B. J., Ong, Y. -K. G., Orkin, A. M., Paiva, E. F., Parr, M. J., Patocka, C., Pellegrino, J. L., Perkins, G. D., Perlman, J. M., Rabi, Y., Reis, A. G., Reynolds, J. C., Ristagno, G., Rodriguez-Nunez, A., Roehr, C. C., Rudiger, M., Sakamoto, T., Sandroni, Claudio, Sawyer, T. L., Schexnayder, S. M., Schmolzer, G. M., Schnaubelt, S., Semeraro, F., Skrifvars, M. B., Smith, C. M., Sugiura, T., Tijssen, J. A., Trevisanuto, D., Van De Voorde, P., Wang, T. -L., Weiner, G. M., Wyllie, J. P., Yang, C. -W., Yeung, J., Nolan, J. P., Berg, K. M., Burdick, M. C., Cartledge, S., Dawson, J. A., Elgohary, M. M., Ersdal, H. L., Finan, E., Flaatten, H. I., Flores, G. E., Fuerch, J., Garg, R., Gately, C., Goh, M., Halamek, L. P., Handley, A. J., Hatanaka, T., Hoover, A., Issa, M., Johnson, S., Kamlin, C. O., Ko, Y. -C., Kule, A., Leone, T. A., Mackenzie, E., Macneil, F., Montgomery, W., O'Dochartaigh, D., Ohshimo, S., Palazzo, F. S., Picard, C., Quek, B. H., Raitt, J., Ramaswamy, V. V., Scapigliati, Andrea, Shah, B. A., Stewart, C., Strand, M. L., Szyld, E., Thio, M., Topjian, A. A., Udaeta, E., Vaillancourt, C., Wetsch, W. A., Wigginton, J., Yamada, N. K., Yao, S., Zace, D., Zelop, C. M., Sandroni C. (ORCID:0000-0002-8878-2611), and Scapigliati A. (ORCID:0000-0002-4044-2343)

Abstract

This is the sixth annual summary of the International Liaison Committee on Resuscitation International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. This summary addresses the most recently published resuscitation evidence reviewed by International Liaison Committee on Resuscitation Task Force science experts. Topics covered by systematic reviews include cardiopulmonary resuscitation during transport; approach to resuscitation after drowning; passive ventilation; minimizing pauses during cardiopulmonary resuscitation; temperature management after cardiac arrest; use of diagnostic point-of-care ultrasound during cardiac arrest; use of vasopressin and corticosteroids during cardiac arrest; coronary angiography after cardiac arrest; public-access defibrillation devices for children; pediatric early warning systems; maintaining normal temperature immediately after birth; suctioning of amniotic fluid at birth; tactile stimulation for resuscitation immediately after birth; use of continuous positive airway pressure for respiratory distress at term birth; respiratory and heart rate monitoring in the delivery room; supraglottic airway use in neonates; prearrest prediction of in-hospital cardiac arrest mortality; basic life support training for likely rescuers of high-risk populations; effect of resuscitation team training; blended learning for life support training; training and recertification for resuscitation instructors; and recovery position for maintenance of breathing and prevention of cardiac arrest. Members from 6 task forces have assessed, discussed, and debated the quality of the evidence using Grading of Recommendations Assessment, Development, and Evaluation criteria and generated consensus treatment recommendations. Insights into the deliberations of the task forces are provided in the Justification and Evidence-to-Decision Framework Highlights sections, and priority knowledge gaps for futu

Published
2022

21. COMPARE LAAO: Rationale and design of the randomized controlled trial ‘COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy’

Author

Huijboom, H.F.M., primary, Maarse, M., additional, Aarnink, E., additional, van Dijk, V.F., additional, Swaans, M.J., additional, van der Heijden, J.F., additional, IJsselmuiden, S., additional, Folkeringa, R., additional, Blaauw, Y., additional, Elvan, A., additional, Stevenhagen, J., additional, Vlachojannis, G.J., additional, van der Voort, P.H., additional, Westra, S., additional, Chaldoupi, M., additional, Khan, M., additional, de Groot, J.R., additional, van der Kley, F., additional, van Mieghem, N., additional, van Dijk, E., additional, Dijkgraaf, M.G., additional, Tijssen, J., additional, and Boersma, L.V.A., additional

Published
2022
Full Text
View/download PDF

26. Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvement

Author

van der Wel, M J, primary, Klaver, E, additional, Pouw, R E, additional, Brosens, L A A, additional, Biermann, K, additional, Doukas, M, additional, Huysentruyt, C, additional, Karrenbeld, A, additional, ten Kate, F J W, additional, Kats-Ugurlu, G, additional, van der Laan, J, additional, van Lijnschoten, I, additional, Moll, F C P, additional, Offerhaus, G J A, additional, Ooms, A H A G, additional, Seldenrijk, C A, additional, Visser, M, additional, Tijssen, J G, additional, Meijer, S L, additional, and Bergman, J J G H M, additional

Published
2021
Full Text
View/download PDF

27. Performance of gastrointestinal pathologists within a national digital review panel for Barrett's oesophagus in the Netherlands: results of 80 prospective biopsy reviews

Author

Klaver, E., Wel, M. van der, Duits, L., Pouw, R., Seldenrijk, K., Offerhaus, J., Visser, Mike, Kate, F. Ten, Biermann, K., Brosens, L.A.A., Doukas, M., Huysentruyt, C., Karrenbeld, A., Kats-Ugurlu, G., Laan, J. van der, Lijnschoten, I. Van, Moll, F., Ooms, A., Tijssen, J., Meijer, S., Bergman, J., Klaver, E., Wel, M. van der, Duits, L., Pouw, R., Seldenrijk, K., Offerhaus, J., Visser, Mike, Kate, F. Ten, Biermann, K., Brosens, L.A.A., Doukas, M., Huysentruyt, C., Karrenbeld, A., Kats-Ugurlu, G., Laan, J. van der, Lijnschoten, I. Van, Moll, F., Ooms, A., Tijssen, J., Meijer, S., and Bergman, J.

Abstract

Contains fulltext : 245220.pdf (Publisher’s version ) (Open Access), AIMS: The histopathological diagnosis of low-grade dysplasia (LGD) in Barrett's oesophagus (BO) is associated with poor interobserver agreement and guidelines dictate expert review. To facilitate nationwide expert review in the Netherlands, a web-based digital review panel has been set up, which currently consists of eight 'core' pathologists. The aim of this study was to evaluate if other pathologists from the Dutch BO expert centres qualify for the expert panel by assessing their performance in 80 consecutive LGD reviews submitted to the panel. METHODS: Pathologists independently assessed digital slides in two phases. Both phases consisted of 40 cases, with a group discussion after phase I. For all cases, a previous consensus diagnosis made by five core pathologists was available, which was used as reference. The following criteria were used: (1) percentage of 'indefinite for dysplasia' diagnoses, (2) percentage agreement with consensus diagnosis and (3) proportion of cases with a consensus diagnosis of dysplasia underdiagnosed as non-dysplastic. Benchmarks were based on scores of the core pathologists. RESULTS: After phase I, 1/7 pathologists met the benchmark score for all quality criteria, yet three pathologists only marginally failed the agreement with consensus diagnosis (score 68.3%, benchmark 69%). After a group discussion and phase II, 5/6 remaining aspirant panel members qualified with all scores within the benchmark range. CONCLUSIONS: The Dutch BO review panel now consists of 14 pathologists, who-after structured assessments and group discussions-can be considered homogeneous in their review of biopsies with LGD.

Published
2021

28. Performance of gastrointestinal pathologists within a national digital review panel for Barrett's oesophagus in the Netherlands: Results of 80 prospective biopsy reviews

Author

Klaver, E, Wel, M, Duits, L, Pouw, R, Seldenrijk, K, Offerhaus, J, Visser, M, Ten Kate, F, Biermann, Katharina, Brosens, L, Doukas, Michail, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J, van Lijnschoten, I, Moll, F, Ooms, A, Tijssen, J, Meijer, S, Bergman, J, Klaver, E, Wel, M, Duits, L, Pouw, R, Seldenrijk, K, Offerhaus, J, Visser, M, Ten Kate, F, Biermann, Katharina, Brosens, L, Doukas, Michail, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J, van Lijnschoten, I, Moll, F, Ooms, A, Tijssen, J, Meijer, S, and Bergman, J

Abstract

Aims The histopathological diagnosis of low-grade dysplasia (LGD) in Barrett's oesophagus (BO) is associated with poor interobserver agreement and guidelines dictate expert review. To facilitate nationwide expert review in the Netherlands, a web-based digital review panel has been set up, which currently consists of eight 'core' pathologists. The aim of this study was to evaluate if other pathologists from the Dutch BO expert centres qualify for the expert panel by assessing their performance in 80 consecutive LGD reviews submitted to the panel. Methods Pathologists independently assessed digital slides in two phases. Both phases consisted of 40 cases, with a group discussion after phase I. For all cases, a previous consensus diagnosis made by five core pathologists was available, which was used as reference. The following criteria were used: (1) percentage of 'indefinite for dysplasia' diagnoses, (2) percentage agreement with consensus diagnosis and (3) proportion of cases with a consensus diagnosis of dysplasia underdiagnosed as non-dysplastic. Benchmarks were based on scores of the core pathologists. Results After phase I, 1/7 pathologists met the benchmark score for all quality criteria, yet three pathologists only marginally failed the agreement with consensus diagnosis (score 68.3%, benchmark 69%). After a group discussion and phase II, 5/6 remaining aspirant panel members qualified with all scores within the benchmark range. Conclusions The Dutch BO review panel now consists of 14 pathologists, who - after structured assessments and group discussions - can be considered homogeneous in their review of biopsies with LGD.

Published
2021

29. Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvement

Author

Pathologie Opleiding, Cancer, AIOS Anesthesiologie, Pathologie Pathologen staf, Pathologie Groep Derksen, Trialbureau Beeld, Zorgeenheid Vaatchirurgie Medisch, MS CGO, van der Wel, M. J., Klaver, E., Pouw, R. E., Brosens, L. A.A., Biermann, K., Doukas, M., Huysentruyt, C., Karrenbeld, A., Ten Kate, F. J.W., Kats-Ugurlu, G., van der Laan, J., van Lijnschoten, I., Moll, F. C.P., Offerhaus, G. J.A., Ooms, A. H.A.G., Seldenrijk, C. A., Visser, M., Tijssen, J. G., Meijer, S. L., Bergman, J. J.G.H.M., Pathologie Opleiding, Cancer, AIOS Anesthesiologie, Pathologie Pathologen staf, Pathologie Groep Derksen, Trialbureau Beeld, Zorgeenheid Vaatchirurgie Medisch, MS CGO, van der Wel, M. J., Klaver, E., Pouw, R. E., Brosens, L. A.A., Biermann, K., Doukas, M., Huysentruyt, C., Karrenbeld, A., Ten Kate, F. J.W., Kats-Ugurlu, G., van der Laan, J., van Lijnschoten, I., Moll, F. C.P., Offerhaus, G. J.A., Ooms, A. H.A.G., Seldenrijk, C. A., Visser, M., Tijssen, J. G., Meijer, S. L., and Bergman, J. J.G.H.M.

Published
2021

41. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

Author

Dangas, George D., Tijssen, Jan G. P., Wöhrle, Jochen, Søndergaard, Lars, Gilard, Martine, Möllmann, Helge, Makkar, Raj R., Herrmann, Howard C., Giustino, Gennaro, Baldus, Stephan, de Backer, Ole, Guimarães, Ana H. C., Gullestad, Lars, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raúl, Schäfer, Ulrich, Seeger, Julia, Tchétché, Didier, Thomitzek, Karen, Valgimigli, Marco, Vranckx, Pascal, Welsh, Robert C., Wildgoose, Peter, Volkl, Albert A., Zazula, Ana, van Amsterdam, Ronald G. M., Mehran, Roxana, Windecker, Stephan, Dangas, G. D., Windecker, S., Mehran, R., Tijssen, J. G. P., Welsh, R. C., Vranckx, P., Valgimigli, M., van Amsterdam, R. G. M., Thomitzek, K., Wildgoose, P., Colombo, A., Prendergast, B., Makkar, R., Mack, M., Webb, J., Marx, Steven O., Corvaja, Nicola, Ghodsi, Newsha, DiStefano, Douglas, Kaufman, David, Bugger, Heiko/0000-0002-3524-0405, Avanzas, Pablo/0000-0002-4958-6108, Twerenbold, Raphael/0000-0003-3814-6542, Kalkman, Deborah/0000-0002-1900-2116, Academic Medical Center, Cardiology, ACS - Heart failure & arrhythmias, University of Zurich, and Windecker, Stephan

Subjects
medicine.medical_specialty, Catheters, Transcatheter aortic, medicine.drug_mechanism_of_action, medicine.medical_treatment, Factor Xa Inhibitor, MEDLINE, 610 Medicine & health, 2700 General Medicine, 030204 cardiovascular system & hematology, 11171 Cardiocentro Ticino, law.invention, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Randomized controlled trial, Valve replacement, law, Ús terapèutic, medicine, 030212 general & internal medicine, Aspirina, Rivaroxaban, Intention-to-treat analysis, Aspirin, business.industry, 10031 Clinic for Angiology, Catèters, Therapeutic use, food and beverages, General Medicine, Surgery, 10209 Clinic for Cardiology, business, medicine.drug
Abstract

Background Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear. Methods We randomly assigned 1644 patients without an established indication for oral anticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months) (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose of 75 mg daily for the first 3 months) (antiplatelet group). The primary efficacy outcome was the composite of death or thromboembolic events. The primary safety outcome was major, disabling, or life-threatening bleeding. The trial was terminated prematurely by the data and safety monitoring board because of safety concerns. Results After a median of 17 months, death or a first thromboembolic event (intention-to-treat analysis) had occurred in 105 patients in the rivaroxaban group and in 78 patients in the antiplatelet group (incidence rates, 9.8 and 7.2 per 100 person-years, respectively; hazard ratio with rivaroxaban, 1.35; 95% confidence interval [CI], 1.01 to 1.81; P=0.04). Major, disabling, or life-threatening bleeding (intention-to-treat analysis) had occurred in 46 and 31 patients, respectively (4.3 and 2.8 per 100 person-years; hazard ratio, 1.50; 95% CI, 0.95 to 2.37; P=0.08). A total of 64 deaths occurred in the rivaroxaban group and 38 in the antiplatelet group (5.8 and 3.4 per 100 person-years, respectively; hazard ratio, 1.69; 95% CI, 1.13 to 2.53). Conclusions In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy. (Funded by Bayer and Janssen Pharmaceuticals; GALILEO ClinicalTrials.gov number, NCT02556203.) Supported by Bayer in collaboration with Janssen Pharmaceuticals. Dr. Dangas reports iving lecture lees from Bayer, receiving grant support, paid to his institution, and lecture fees from Daiichi Sankyo, and previously holding equity in Medtronic; Dr. Mollmann, receiving lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer; Dr. Makkar, receiving grant support, consulting fees, and travel support from Abbott Vascular, grant support, lecture fees, and travel support from Edwards Lifesciences, and grant support and consulting fees from Medtronic and Boston Scientific; Dr. FIerrmann, receiving grant support, paid to his institution, from Abbott Vascular and Boston Scientific and grant support, paid to his institution, and consulting fees from Edwards Lifesciences and Medtronic; Dr. Giusrino, receiving consulting fees from Bristol-Myers Squibb/Pfizer; Dr. De Backer, receiving lecture fees from Boston Scientific; Dr. Guimaraes, being employed by Cardialysis; Dr. Mack, serving as a trial coprimary investigator for Edwards Lifesciences and Abbott Vascular and serving as a study chair for Medtronic; Dr. Schafer, receiving grant support from the Medicines Company; Dr. Thomitzek, being employed by and holding stock in Bayer; Dr. Valgimigli, receiving lecture fees from AstraZeneca, Als'imedical CID, Vifor Pharma, and Medscape, grant support and lecture fees from 'Ceram, consulting fees and lecture fees from Abbott Vascular, Bayer, and Bristol-Myers Squibb, and consulting fees from Daiichi Sankyo, Opsens, CoreFIDW, Idorsia Pharmaceuticals, and iVascular; Dr. Vranekx, receiving fees for serving on a speakers bureau from Daiichi Sankyo, lecture tees from AstraZeneca, and fees for serving on a steering committee and travel support from CSL Behring; Dr. Welsh, receiving grant support and honoraria from AstraZeneca, Bayer, and Boehringer Ingelheim; Dr. Wildgoose, being employed by and holding stock in Janssen Pharmaceuticals; Dr. Volkl, being employed by Janssen Pharmaceuticals; Dr. van Amsterdam, being employed by Cardialysis; Dr. Zazula, being employed by Bayer; Dr. Mehran, receiving advisory board fees and consulting fees from Sanofi-Aventis and Janssen, receiving lecture fees from Bayer, receiving grant support, paid to her institution, and lecture fees from Daiichi Sankyo, and previously holding equity in Medtronic; and Dr. Windecker, receiving grant support, paid to his institution, advisory board fees, and travel support from Amgen and grant support, paid ro his institution, from Abbott Vascular, Bayer, Bristol-Myers Squibb, CSL Behring, Boston Scientific, Bic rronik, Medtronic, Edwards Lifesciences, Polares Medical, and Sinomed. No other potential conflict of interest relevant to this article was reported. Windecker, S (reprint author), Windecker, S (reprint author) stephan.windecker@insel.ch

Published
2020

42. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial

Author

Tomaniak, M., Chichareon, P., Takahashi, K., Kogame, N., Modolo, R., Chang, C.C., Spitzer, E., Neumann, F.J., Plante, S., Antolin, R. Hernández, Jambrik, Z., Gelev, V., Brunel, P., Konteva, M., Beygui, F., Morelle, J.F., Filipiak, K.J., Geuns, R.J.M. van, Soliman, O., Tijssen, J., Rademaker-Havinga, T., Storey, R.F., Hamm, C., Steg, P.G., Windecker, S., Onuma, Y., Valgimigli, M., Serruys, P.W., Tomaniak, M., Chichareon, P., Takahashi, K., Kogame, N., Modolo, R., Chang, C.C., Spitzer, E., Neumann, F.J., Plante, S., Antolin, R. Hernández, Jambrik, Z., Gelev, V., Brunel, P., Konteva, M., Beygui, F., Morelle, J.F., Filipiak, K.J., Geuns, R.J.M. van, Soliman, O., Tijssen, J., Rademaker-Havinga, T., Storey, R.F., Hamm, C., Steg, P.G., Windecker, S., Onuma, Y., Valgimigli, M., and Serruys, P.W.

Abstract

Contains fulltext : 225457.pdf (Publisher’s version ) (Closed access), AIMS: To evaluate long-term safety and efficacy of ticagrelor monotherapy in patients undergoing percutaneous coronary interventions (PCIs) in relation to chronic obstructive pulmonary disease (COPD) at baseline and the occurrence of dyspnoea reported as adverse event (AE) that may lead to treatment non-adherence. METHODS AND RESULTS: This is a non-prespecified, post hoc analysis of the randomized GLOBAL LEADERS trial (n = 15 991), comparing the experimental strategy of 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) after PCI with the reference strategy of 12-month DAPT followed by 12-month aspirin monotherapy. Impact of COPD and dyspnoea AE (as a time-dependent covariate) on clinical outcomes was evaluated up to 2 years. The primary endpoint was a 2-year all-cause mortality or non-fatal, centrally adjudicated, new Q-wave myocardial infarction. The presence of COPD (n = 832) was the strongest clinical predictor of 2-year all-cause mortality after PCI [hazard ratio (HR) 2.84; 95% confidence interval (CI) 2.21-3.66; P adjusted = 0.001] in this cohort (n = 15 991). No differential treatment effects on 2-year clinical outcomes were found in patients with and without COPD (primary endpoint: HR 0.88; 95% CI 0.58-1.35; P = 0.562; P int = 0.952). Overall, at 2 years dyspnoea was reported as an AE in 2101 patients, more frequently among COPD patients, irrespective of treatment allocation (27.2% in experimental arm vs. 14.5% in reference arm, P = 0.001). Its occurrence was not associated with a higher rate of the primary endpoint (P adjusted = 0.640) in the experimental vs. the reference arm. CONCLUSION: In this exploratory analysis, COPD negatively impacted long-term prognosis after PCI. Despite higher incidence of dyspnoea in the experimental arm, in particular among COPD patients, the safety of the experimental treatment strategy appeared not to be affected. CLINICAL TRIAL REGISTRATION UNIQUE IDENTIFIER: NCT01813435.

Published
2020

43. Prognostic implications of resting distal coronary-to-aortic pressure ratio compared with fractional flow reserve : a 10-year follow-up study after deferral of revascularisation

Author

Wijntjens, G. W.M., van de Hoef, T. P., Meuwissen, M., Echavarría-Pinto, M., Murai, T., Stegehuis, V. E., Koch, K. T., Chamuleau, S. A., Voskuil, M., de Winter, R. J., Tijssen, J. G.P., Piek, J. J., Wijntjens, G. W.M., van de Hoef, T. P., Meuwissen, M., Echavarría-Pinto, M., Murai, T., Stegehuis, V. E., Koch, K. T., Chamuleau, S. A., Voskuil, M., de Winter, R. J., Tijssen, J. G.P., and Piek, J. J.

Published
2020

44. Prognostic implications of resting distal coronary-to-aortic pressure ratio compared with fractional flow reserve: a 10-year follow-up study after deferral of revascularisation

Author

Team Medisch, Circulatory Health, Wijntjens, G. W.M., van de Hoef, T. P., Meuwissen, M., Echavarría-Pinto, M., Murai, T., Stegehuis, V. E., Koch, K. T., Chamuleau, S. A., Voskuil, M., de Winter, R. J., Tijssen, J. G.P., Piek, J. J., Team Medisch, Circulatory Health, Wijntjens, G. W.M., van de Hoef, T. P., Meuwissen, M., Echavarría-Pinto, M., Murai, T., Stegehuis, V. E., Koch, K. T., Chamuleau, S. A., Voskuil, M., de Winter, R. J., Tijssen, J. G.P., and Piek, J. J.

Published
2020

45. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial

Author

Tomaniak, Mariusz, Chichareon, P, Takahashi, K, Kogame, N, Modolo, R, Chang, Chun-Chin, Spitzer, Ernest, Neumann, FJ, Plante, S, Antolin, RH, Jambrik, Z, Gelev, V, Brunel, P, Konteva, M, Beygui, F, Morelle, JF, Filipiak, KJ, van Geuns, Robert Jan, Soliman, Osama, Tijssen, J, Rademaker-Havinga, T, Storey, RF, Hamm, C, Steg, PG, Windecker, S, Onuma, Yoshinobu, Valgimigli, M (Marco), Serruys, PWJC (Patrick), Tomaniak, Mariusz, Chichareon, P, Takahashi, K, Kogame, N, Modolo, R, Chang, Chun-Chin, Spitzer, Ernest, Neumann, FJ, Plante, S, Antolin, RH, Jambrik, Z, Gelev, V, Brunel, P, Konteva, M, Beygui, F, Morelle, JF, Filipiak, KJ, van Geuns, Robert Jan, Soliman, Osama, Tijssen, J, Rademaker-Havinga, T, Storey, RF, Hamm, C, Steg, PG, Windecker, S, Onuma, Yoshinobu, Valgimigli, M (Marco), and Serruys, PWJC (Patrick)

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results